EMA´s Communication Perception Survey 2017

In May 2017, the European Medicines Agency (EMA) carried out a survey on its communication activities. The purpose was to assess, qualitatively and quantitatively, how EMA’s communication to the public is perceived and valued by its partners and stakeholders and whether they are satisfied with the services provided. The results will be used to monitor communication perception and support continual improvement of communication activities and products.

The survey comprised three questionnaires in total: one for partners, one for stakeholders and one for website visitors. The three questionnaires were similar, but the one to partners also aimed at capturing the level of satisfaction with EMA’s efforts to coordinate key information within the EU Regulatory Network.

The questionnaires focused on EMA communication activities to the general public (i.e. EMA information made public mainly through the EMA website such as press releases and news announcements).

1,774 selected individuals were asked to fill in the questionnaire (986 stakeholders and 788 partners). Of these, 417 (252 stakeholders and 165 partners) responded.

  • The response rate was 23%. A total of 198 responses were received t

  • hrough the EMA website
    and these were analysed separately from targeted stakeholders and partn
  • ers.
  • 32,500 followers at the end of 2017) twice (11 May and 31 May, 2017), resulting in 20 responses.
  • The response rate from media representatives was low (around 11% of those contacted responded,
    making up 10% of total stakeholder responses).
  • EMA runs separate, targeted surveys for this 
  • stakeholder group taking into account their specific needs. Combining stakeholders, partners and web users, a total of 615 responses were analysed.

If want, you can download the complete PDF clicking here.


EMA’s publication of clinical data a success

First report on unprecedented transparency policy shows high user satisfaction

The European Medicines Agency (EMA) has published the first report on the implementation of its flagship policy on the publication of clinical data (Policy 0070). Under this policy citizens, including researchers and academics, can directly access thousands of pages from clinical reports submitted by pharmaceutical companies to EMA in the context of marketing authorisation applications for new medicines as of 1 January 2015. Clinical reports give information on the methods used and results of clinical trials conducted to demonstrate the safety and efficacy of medicines.

The report covers one year from the launch of EMA’s clinical data websiteExternal link icon on 20 October 2016 and lists the 50 medicines for which clinical data were published, including orphan, paediatric, biosimilar and generic medicines, as well as the corresponding 54 regulatory dossiers. These data have attracted a total of 3,641 users, resulting in 22,164 document ‘views’ and 80,537 ‘downloads’ for non-commercial research purposes.

The report sheds light on the total number of documents published, the amount of commercially confidential information (CCI) redacted and the anonymisation techniques used. EMA accepted 24% of CCI redactions proposed by pharmaceutical companies, with the result that only 0.01% of 1.3 million pages published contained CCI redactions.

Of the total respondents:

  • 62% were affiliated to the pharmaceutical industry
  • 14% to academia
  • 8% were patients
  • 8% healthcare professionals

The report summarises the reasons of the different user groups for accessing the data and their views on its usability:

“It shows that very few respondents disagree with EMA’s rationale for developing the policy”

“Most respondents strongly agree that publishing clinical data increases public trust in EMA’s decision-making and that it allows the reassessment of clinical data”

 The Agency also provided one-on-one assistance to individual companies to prepare them for the publication of clinical data. As a result, EMA published an average of six dossiers a month in the period from October 2017 to May 2018, reaching the 100th published dossier milestone on 29 May 2018.

 


How the EU Agencies contribute to the lives of everyone in Europe

The EU Agency, shows How are they contribuing  to the lives of everyone in Europe with the creation of this new clip from the EU Agencies Network:


Lymph node fibrosis: a structural barrier to unleashing effective vaccine immunity


Statement from FDA Commissioner, on agency’s continued efforts relating to compounded drugs for patients who cannot use an FDA-approved drug

The FDA is aware of many pharmacies that compound topical pain creams comprised of multiple ingredients. Oftentimes, at least one of the ingredients is an active ingredient in an FDA-approved topical pain cream, such as lidocaine. The remaining ingredients may be active ingredients in drugs approved by the FDA for non-topical administration to treat non-pain related indications, such as antidepressants, anticonvulsants, antivirals and narcotics.

Clinicians and patients may not be aware of potential safety risks, or the potential lack of effectiveness, associated with certain ingredients and combinations of ingredients in their compounded topical pain creams. In the coming months, the FDA intends to announce its plan to improve the information available about compounded topical pain creams, which will help inform reimbursors’ and the medical community’s decisions about these products.

The FDA is also taking steps to ensure that outsourcing facilities, a new type of compounder created by federal legislation enacted in 2013, are compounding drugs from bulk drug substances for which there is a clinical need. In March of this year, the agency issued a draft guidance that describes how the FDA proposes to evaluate clinical need. Soon, the FDA will be announcing its plan to secure input from medical professionals about clinical need for the nominated substances.

In addition, the FDA is inspecting compounding facilities to assess whether drugs that are essentially copies of FDA-approved drugs are being compounded for patients who could use an FDA-approved drug. As we described in our January 2018 communication, such a practice creates significant public health risks because patients are unnecessarily exposed to drugs that have not been shown to be safe and effective, and it undermines the integrity of the premarket approval processes that Congress put in place to protect patients from unsafe, ineffective, or poor quality drugs.

Furthermore, the FDA is inspecting compounding facilities not registered as outsourcing facilities to confirm that they are distributing compounded drugs pursuant to valid patient-specific prescriptions. The prescription requirement helps to ensure that drugs compounded in these facilities, which are not FDA-approved, are provided to patients based on individual patient needs.


First two CAR-T cell medicines recommended for approval in the European Union

The European Medicines Agency (EMA) has recommended the first two marketing authorisations for chimeric antigen receptors (CAR) T-cells medicines in the European Union (EU). Both of them, are advanced therapies for blood cancer. They belong to a new generation of personalised cancer immunotherapies that are based on collecting and modifying patients’ own immune cells to treat their cancer.

Both advance therapies, are also the first medicines supported through EMA’s PRIority MEdicines (PRIME) scheme to receive positive opinions from the Committee for Medicinal Products for Human Use (CHMP). The voluntary scheme provides early and enhanced scientific and regulatory support to medicines that have the potential to address, to a significant extent, patients’ unmet medical needs.

“CAR-T cells transform the fight against serious and often fatal diseases in the EU,” said Dr Martina Schüssler-Lenz, chair of the Committee for Advanced Therapies (CAT). “Those two advance therapies medicines, offer an innovative approach where patients’ cells are reprogrammed and reinjected to attack the cancer.”

“Innovative treatments such as CAR-T cells have potential to change the outlook for patients with cancer, but they also come with new scientific and regulatory challenges,” commented Dr Tomas Salmonson, Chair of the CHMP.

“From the beginning, we have worked to establish a robust system of data collection for the post-authorisation phase that would suit the specificities of these two medicines. We have used a wide range of tools – scientific advice, a specific workshop on patient registries for CAR-T cells, PRIME, to name just a few, to enable us to define the methods to tightly monitor the benefit-risk profile of these medicines and manage their risks once they are on the market, so that patients can benefit from these innovative treatments.”

 

 


Sermes CRO, a PSN compan in Spain attended the SETGYC Annual Congress

Sermes CRO, our PSN company in Spain, attended the 9th Congress of the SETYC – Spanish Society of cell and gen therapies

The Spanish Society for Gene and Cell Therapy (SETGyC) is a platform that aims to promote and support fundamental, translational and clinical research in these areas, as well as collaboration with institutions, biotechnological and pharmaceutical companies for development of new therapies. The complexity of these studies often requires a multidisciplinary approach and our Society is an ideal forum to find colleagues with whom to share knowledge and procedures for the development of new, more effective and safe therapies as well as good practice in gene and cell therapy products and in the clinical application of these products. Many of the teams that have implemented clinical trials on advanced therapies are members of the SETGyC, which aims to facilitate the translation of fundamental research to medical applications complying with European regulations for cell therapy and gene therapy, to advise on these aspects and to defend the good practice in cell production and in clinical application of cellular products.

The main objectives of  the Congress were:

• To boost the profile of gene and cell therapy in Spain and internationally

• To facilitate communication and exchange of expertise and resources between professionals

• To provide advice and advocacy in all themes relating to new and existing gene and cell therapies

 

Sermes CRO, as a company focus on the development  of Advance Therapies (ATMPs) in different therapeutic areas, and also working with different companies and investigational groups at hospital level, submitted two posters showing their collaboration with one of the most important projects in cell therapy.

The posters are created from the project with Mesenchymal Stromal cells (MSCs) of the Hospital Puerta de Hierro and the Principal Investigator Dr. Jesús vaquero. This new therapy, offers a new treatment alternative for patients with complete and inclomplete SCI  in Chronic established Paraplegia.

Spain is one of the leading countries in Europe with regard to the number of sponsors of advanced therapy medicinal products (ATMPs), which are mainly not-for-profit institutions. It is also a leader in the number of ATMPs undergoing clinical development programs. Source: Maciulaitis et al. (2012). Molecular Therapy; 20, 479–482 Objectives of the SETGyC Situation in Spain Through its activities, the SETGyC hopes to support fundamental and translational research aimed at the advancement of gene and cell therapy in Spain by promoting the incorporation of the latest international developments in the field.


CAT monthly report of application procedures, guidelines and related documents on advanced therapies

The Committee for Advanced Therapies (CAT) held its 102nd CAT meeting on 14 – 16 March 2018.

The CAT Monthly Report includes statistical data on CAT scientific recommendations on Advanced Therapy Medicinal Product (ATMP) classification, certifications, initial evaluations, CAT contributions to Scientific Advice and Paediatric Investigation Plans, as well as variations, line extensions, renewals. Scientific recommendation on advanced therapy product classification Further to consultation with the European Commission, the CAT finalised 1 scientific recommendation on the classification of advanced therapy medicinal products.

The following product was classified as a tissue engineered product:

• Autologous expanded auricular chondrocytes, intended for surgical implantation for the repair of microtia. Organisational matters

• CAT adopted the public report on the expert meeting on adeno-associated viral vector-based gene therapy medicinal product, which was held at the EMA on 6 September 2017. The report will be published shortly.

• CAT adopted the Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells. The guideline, which is a revision of the guideline on genetically modified cells published in April 2012, will be released for public consultation by June 2018.

• CAT discussed the programme of the joint CHMP/PDCO/CAT Strategic Review and Learning meeting that will take place in Oslo, Norway on 7 – 9 May 2018 under the auspices of the Bulgarian presidency of the European Union.


Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP)

 Six medicines recommended for approval, including one orphan

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended six medicines for approval, including one orphan medicine1, at its March 2018 meeting.

  • The CHMP recommended granting a conditional marketing authorisation for Rubraca(rucaparib), for the treatment of relapsed or progressive ovarian cancer.
  • Juluca (dolutegravir / rilpivirine) received a positive opinion for the treatment of human immunodeficiency virus (HIV) infection.
  • Biosimilars: Kanjinti (trastuzumab) for the treatment of breast and gastric cancer; and Zessly (infliximab) for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.
  • Generics: received a positive opinion from the CHMPPemetrexed Krka(pemetrexed), for the treatment of malignant pleural mesothelioma and non-small cell lung cancer; and Prasugrel Mylan (prasugrel), for the prevention of atherothrombotic events.

 

Negative opinions on two new medicines

  • Dexxience (betrixaban). Dexxience was expected to be used for the prevention of venous thromboembolism.
  • The Committee also adopted a negative opinion for Eladynos (abaloparatide). Eladynos was intended to be used to treat osteoporosis.

 

Three recommendations on extensions of therapeutic indication

The Committee recommended extensions of indications for CabometyxIvemend and Repatha.

Start of re-examination of recommendation on extension of therapeutic indication

The applicant for Sutent (sunitinib) has requested a re-examination of the Committee’s negative opinion for this medicine adopted at the February 2018 meeting. 

Start of referral: omega-3 fatty acid medicines

The CHMP started a review of the use of omega-3 fatty acid medicines in patients who have had a heart attack, following research showing that these oral products may not prevent recurrence of heart disease or stroke.

 

 

 

 


The EMA publishes a Q&A document on Rare Riseases

 

In support of Rare Disease Day, the EMA has published a question-and-answer document addressing common misunderstandings about the meaning of orphan designation and other aspects pertaining to orphan medicines.

This document explains key concepts in the regulation of medicines for rare diseases such as orphan designation and significant benefit. The Q&A document is available by clicking here.

For more information about orphan designation please click here.


Patients interested in working with the European Medicines Agency

The European Medicine Agency, as part of their endeavours to involve patients in all aspects of medicines evaluation and regulatory processes,  wants to share  the linked image  along with the message that any patients interested in working with the European Medicines Agency can register their interest and further share this link

https://fmapps.emea.europa.eu/stakeholders/signup.php

 

Questions and answers – EMA individual experts’ stakeholder database: patients and consumers are also available.


New Videos Available on why EMA matters to European citizens

The European Medicines Agency (EMA) has published three video animations to explain how it ensures that medicines are effective and safe for citizens across the European Economic Area (EEA).

  • The first video explains that the Agency assesses, supervises and monitors medicines long before they appear in pharmacies and hospitals, and the whole time they are on the market, by bringing together the expertise from the European network.
  • The second animation describes the journey of a medicine from initial laboratory tests to its authorisation by EMA and the European Commission.
  • Finally, the third video focuses on how the Agency collects information on side effects from new clinical studies, scientific publications and reports from doctors, pharmacists and patients to keep medicines safe.

The videos are available on EMA’s website and on the official EMA YouTube channel.

 


Strengthened guidance on follow-up and risk management for ATMP developers

The European Medicines Agency (EMA) has released a draft revised guideline on the safety and efficacy follow-up and risk management of advanced therapy medicinal products (ATMPs) for a three-month public consultation. The revision is part of the joint action plan published by the European Commission and EMA in October 2017 to streamline procedures and better address the specific requirements of ATMP developers.

This guideline replaces ‘Guideline on safety and efficacy follow-up – risk management of Advanced 10 Therapy Medicinal Products’ (EMEA/149995/2008)

This is the first revision of the ATMP guideline and focuses on safety and efficacy follow-up and risk management. The guideline now takes into consideration the experience gained with the authorisation of these medicines, as well as the experience with scientific advice and protocol assistance.

It also provides advice on early detection of risks during development and provides a framework for the effective mitigation of their consequences for patients. In addition, the revision gives methodological advice on the design of appropriate post-authorisation studies to follow up on the safety and efficacy of these medicines.

Please to see the full guide, click the link below:

ATMPs Guide reviwed2018


PSNResearch Proud to have Supported MND Association International Symposium

PSNResearch was Silver Sponsor of the 27th International Symposium on ALS/MND being run by the Motor Neurone Disease Association.

 

The Symposium is the world’s largest medical and scientific conference solely about Motor Neurone Disease / ALS. The 27th International Symposium on ALS/MND held in Boston, USA on 8 – 10 December 2017, over 1,200 delegates attended to hear about progress in research on a number of topics including pre-approval access, telemedicine, emerging markers, and cognitive change.

 


An overview of the EU’s orphan designation programme

The Agency is responsible for reviewing applications from sponsors for orphan designation. To qualify for orphan designation, a medicine must meet a number of criteria:

  • It must be intended for the treatment, prevention or diagnosis of a disease that is life-threatening or chronically debilitating;
  • The prevalence of the condition in the EU must not be more than 5 in 10,000 or it must be unlikely that marketing of the medicine would generate sufficient returns to justify the investment needed for its development;
  • No satisfactory method of diagnosis, prevention or treatment of the condition concerned can be authorised, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition.

The EU’s orphan designation programme was launched in the year 2000 to encourage companies to research and develop medicines for rare diseases.

To date, over 1,900 medicines have been designated as orphan medicines, giving access to specific incentives that make it more attractive for companies to develop them. By the end of 2017 over 140 of these medicines were on the market, providing treatment options for patients who previously often had none.

The new factsheet published by European Medicines Agency today explains what a rare disease is, how the EU programme works and what incentives are made available to developers.


FDA clears stereotactic radiotherapy system for use in treating breast cancer

Radiation therapy is an important treatment option for cancer patients.

Approximately 60 percent of all cancer patients will be treated with some form of radiation therapy. During radiation therapy, tumor cells are killed when their DNA is damaged by the radiation being absorbed into them. While radiation therapy has the potential to kill tumor cells, it can also damage healthy tissue around the tumor.

The GammaPod system is intended for use in the non-invasive stereotactic delivery of a radiation dose to a portion (partial volume) of the breast in conjunction with breast conserving treatment. During the procedure, radiation is delivered to specific areas of the breast. The GammaPod has not been shown to be as effective as whole breast radiation therapy (WBRT) and is not intended to replace WBRT.

The GammaPod system is a dedicated stereotactic radiation therapy technology designed to treat breast cancer. GammaPod uses thousands of focused beams of radiation from 36 rotating radioactive Cobalt-60 sources in combination with a two-layer, vacuum-assisted cup that immobilizes the breast to achieve a more accurate delivery of radiation. The GammaPod design to immobilize the breast during treatment provides the benefit of minimizing the radiation dose to the surrounding healthy tissues in the breast, heart and lungs.

The FDA reviewed scientific evidence including a clinical study of 17 patients that tested the feasibility of accurately delivering the prescribed dose to the breast tumor while minimizing radiation to the healthy tissue. The clinical evidence supports delivering the prescribed dose to the breast tumor with minimal radiation-induced side effects such as skin redness or erythema.

 


Merry Christmas from PSN Research Team!!!


The EMA: Brexit update, Annual work programme and Budget for 2018

 

How is the current situation with The EMA?

This is the first meeting of the Board since the General Affairs Council (Art.50) of 20 November and the decision of the EU 27 Member States to relocate the Agency to Amsterdam. EMA now has just over 15 months to prepare for the move and take up its new seat in Amsterdam by 30 March 2019 at the latest.

EMA’s collaboration with the Netherlands commenced promptly and agreement has been reached on the joint governance structure with plans to progress activities within five work streams relating to the temporary and permanent premises, staff relocation, financial and legal aspects, and external communication.

The EU27 Member States and EMA have developed a methodology for the redistribution of the work currently carried out by the UK’s Medicines & Healthcare products Regulatory Agency (MHRA) and Veterinary Medicines Directorate (VMD). The joint redistribution plan reflects the strengthened capacity of the European medicines regulatory network. The risk-based methodology takes into account the diverse expertise in the network and the workload associated with the medicines. EMA will communicate details of the methodology and next steps in early 2018.

What will be the 2018 work programme and budget for the EMA?

The EMA is preparing the UK’s withdrawal from the EU an what will be the impact on the activities of the Agency. This became clear in the discussion on the Agency’s work programme and the budget for 2018-2019.

The Board adopted a budget of 337 million euros for 2018, a 2% increase over the previous year, driven primarily by an increase in fee-generating activities. The budget for 2018 includes provisions for Brexit-related costs such as IT-related relocation expenses and costs of the physical relocation of the Agency staff and assets. As the relocation process evolves, the budget will need to be monitored carefully and any additional costs that cannot be absorbed should be discussed with the European Commission.

How is going the development of the EU clinical trial portal and database for the EU Clinical Trial Regulation?

The development of the EU Portal and Database is making important progress. A partially-completed version of the system has been subjected to user acceptance testing by representatives of the European Commission, Member States, academia, pharmaceutical industry and contract research organisation (CRO) associations throughout November, while technical testing and further development continue in parallel.

This is the most ambitious IT development project so far required by the EU pharmaceutical legislation. The Agency is working hard in collaboration with Member States, stakeholders and the developers to deliver a good, functional system to support the needs of EU clinical research, and to have the Clinical Trial Regulation enter in operation as soon as practicable.


The EMA relocated to Amsterdam (Netherlands)

On 29 March 2017, the United Kingdom (UK) notified the European Council of its intention to withdraw from the European Union (EU), a process known as ‘Brexit’. EMA is making preparations to ensure that the Agency can continue to deliver on its mission and protect public and animal health after the UK leaves the EU on 30 March 2019, the date currently set by the timeframe provided in Article 50 of the Treaty on European Union.

The EU 27 Member States took this decision on 20 November in the margins of the General Affairs Council (Article 50) of the European Council

The Agency will begin working immediately with the Dutch government to prepare for the move and take up its operations in Amsterdam on 30 March 2019 at the latest.

EMA and the Netherlands will establish a joint governance structure to steer and oversee the relocation project.

In early December 2017, the Agency will publish a monitoring chart on its website that will allow stakeholders to track progress.

Amsterdam was one of 19 offers to host EMA submitted by the Member States at the end of July 2017. For more information, see Background to relocation decision.


New guidelines on good manufacturing practices for advanced therapies

The European Commission has published a set of guidelines on good manufacturing practice (GMP) specific to advanced therapy medicinal products (ATMPs).

ATMPs are medicines for human use that are based on genes or cells. These therapies offer ground-breaking new opportunities for the treatment of diseases and injuries. They are particularly important for severe, untreatable or chronic diseases for which conventional approaches have proven to be inadequate.

The new guidelines adapt the European Union GMP requirements to the specific characteristics of ATMPs and address the novel and complex manufacturing scenarios utilised for these products. The guidelines foster a risk based approach to manufacture and testing of such products.

The guidelines ensure that these novel medicinal productsare consistently produced and controlled according to high quality standards, for the benefit and the safety of patients. This initiative is part of the joint action plan launched by the Directorate General for Health and Food Safety (DG SANTE) and the European Medicines Agency (EMA) in October 2017 to foster the development of ATMPs.

The European Commission drafted these guidelines with extensive input from the Agency’s Committee for Advanced Therapies (CAT) and GMP/Good distribution parctice (GDP) inspectors working group (GMDP IWG), together with national competent authorities and other external stakeholders. The adaptations introduced in the GMP framework for ATMPs will continue ensuring a high level of quality for ATMPs and a high level of patient protection.


Go-live planning of the new EudraVigilance system

The EudraVigilance System is going to be scheduled for downtime from 8th  to 21st of  November 2017.

The Agency will be releasing the new EudraVigilance system on 22th of November. This follows the EMA Management Board announcement in May that the EudraVigilance (Human) system has achieved full functionality. A number of planned tasks and activities are necessary to prepare for the release of the new EudraVigilance system, requiring a downtime period of 10 business days from 8 to 21 November. The scheduled downtime will affect a number of key EudraVigilance functionalities and several other IT systems and business processes.

For more information on the impacted IT systems, including EudraVigilance, business processes and the alternative arrangements, please click here or on the link below:

EudraVigilance System downtime


PSN Research at 25th UEG Week Barcelona 2017

Taking place for the 25th time, UEG Week is the largest and most prestigious GI meeting in Europe and is now a global congress. UEG Week attracts around 14,000 participants each year, from around the world.

UEG, or United European Gastroenterology Week is an opportunity to present new research and thinking across a wide range of digestive disease areas, cutting-edge post-graduate teaching sessions, some of the best GI abstracts and posters and simultaneous live streams to a global audience and endoscopic, ultrasound and surgical hands-on training.

The focus for the 25th UEG Week 2017 in Barcelona will be to advance science and link people in the global GI community. UEG’s mission is to continuously improve standards of care in gastroenterology, and promote ever greater understanding of digestive and liver disease – among the public and medical experts alike.

 

For further information please clink the link below:

https://live.ueg.eu/week/

 


Sermes CRO a PSN Research Company is a Tester of the New EMA´s EU Portal (UATs)

The EMA (European Medicines Agency), retakes the development of the new portal for the online presentation of clinical trials at European level (UATs European portal).
This October 2017 will take place the next step, “test the new portal by a group of experts” carefully selected by EMA itself. In total, the EMA has entrusted 16 European representatives with the task of testing “onsite” the new Portal (UATs) through on-site E2E scenarios, in a face-to-face manner in their offices in London.

EUCROF (European CRO Federation), has determined that Sermes CRO a PSN Research Company, represented by their Head of Unit of start-up (UPM), Lidya Dominguez, will be person chosen to go to the offices of the EMA and to carry out the “on-site” UATs test to analyze possible errors and To bring new ideas of improvement to implant in the Portal.

For more information, click on the following links:

Presentation of Eu Portal and Database project


The EMA presents the EU regulatory system

The European Medicines Agency (EMA)  hosted an awareness session to present the European Union’s (EU) medicines regulatory system and EMA’s role in it to international regulators and non-governmental organisations.

All the speakers were part of the Agency and will present on the European medicines regulatory network and the various activities carried out by EMA as part of it. The issue will be to show a clear understanding of how medicines are regulated in different parts of the word is of prime importance in an increasingly globalised world where regulators rely on close cooperation.

Topics include:

  • European Union (EU) marketing authorisation procedures
  • Support to innovation
  • Benefit/risk assessment of new medicines
  • Pharmacovigilance activities
  • Stakeholder engagement

The European medicines regulatory system is based on a network of around 50 regulatory authorities from the 31 EEA countries (28 EU Member States plus Iceland, Liechtenstein and Norway), the European Commission and EMA.

This network is what makes the EU regulatory system unique. The network is supported by a pool of thousands of experts drawn from across Europe, allowing it to source the best possible scientific expertise for the regulation of medicines in the EU and to provide scientific advice of the highest quality.

EMA and the Member States cooperate and share expertise in the assessment of new medicines and of new safety information. They also rely on each other for exchange of information in the regulation of medicine, for example regarding the reporting of side effects of medicines, the oversight of clinical trials and the conduct of inspections of medicines’ manufacturers. This works because EU legislation requires that each Member State operates to the same rules and requirements regarding the authorisation and monitoring of medicines.

For more information, please see the programme.


Addendum on estimands and sensitivity analysis to the guideline on statistical principles in clinical trials

 

The European Medicines Agency has released for public consultation following guidance document:

The E9(R1) addendum aims to clarify and extend ICH E9 by elaborating on the choice of estimand and sensitivity analysis in clinical trials, providing a framework to align its planning, design, conduct, analysis and interpretation. Having clarity in the trial objectives and accounting explicitly for intercurrent events when describing the treatment effect of interest at the planning stage of a clinical trial are crucial for a clear description of the effects of a medicine.

The proposed framework aims to facilitate dialogue for the disciplines involved at the planning level of the trial and also between sponsors and regulators regarding the treatment effects of interest that a clinical trial should address. The statistical analysis, aligned to the estimand, will be associated with assumptions and data limitations, the impact of which can be investigated through sensitivity analysis, whose definition and role are clarified in this addendum.

Deadline for comments will be 28 February 2018.

Please for more information please click on the link below:

European regulatory system for medicinesr brochure

EMA document


Advances in Stem Cell Therapy for Lung Diseases

University of North Carolina Health Care researchers have made strides toward a stem cell treatment for lung diseases such as pulmonary fibrosis, COPD, and cystic fibrosis.

In fact, they are discussing the start of clinical trials with regulatory authorities.

The team discussed its work in two recent studies. One proved that it is possible to isolate lung stem cells with a relatively non-invasive procedure. The other showed that stem cells reduce fibrosis in rats with pulmonary fibrosis.

“This is the first time anyone has generated potentially therapeutic lung stem cells from minimally invasive biopsy specimens,” Dr. Jason Lobo, director of the university’s lung transplant and interstitial lung disease program, said in a press release. He was co-senior author of both studies.

The research team had previously homed in on stem and support cells they could isolate from a lung tissue sample and grow in a lab. The tissue formed sphere-like structures in a lab dish, prompting the scientists to call them lung spheroid cells.

In 2015, the team showed that these cells had potent regenerative properties in animals with lung diseases. In fact, the stem cells they cultivated outperformed another type called mesenchymal stem cells.

For further information, please check the links below:


The EMA: Science and innovation for better medicines

PATIENTS AND THEIR NEEDS ARE AT THE CENTER OF ALL ACTIVITIES OF THE AGENCY

The European Medicines Agency (EMA) ensures that medicines which are prescribed and used across the European Union (EU) are Safe, Effective and of Good Quality.All of them are carefully evaluated by the bests scientific experts through the European regulatory network assuring each new medicine it is recommended for authorisation if the benefits for the patients outweigh the risks of possible side effects.

The document created, entitled Enabling science that works for patients (at link below), try to explain  how The EMA promotes science and innovation in order to find better medicines, collaborates closely with patients to understand their point of view and to make sure that new medicines address their needs,   providing also a scientific advice and guidance to encourage the development of new and innovative medicines, especially in areas with limited treatment options such as rare diseases and illnesses in children.

EMA involves patients, consumers and their representative organisations in all decisions made during the lifecycle of a medicine in the:

  • Development of policies
  • Regulatory guidance
  • The evaluation and safety monitoring of medicines

To see the deatiled leaflet created by The EMA, pleach clink on the link below:

Enabling science that works for patients


A unique source of information on safety and effectiveness of authorised drugs is registered as EU trade mark

The EU PAS Register was launched in November 2010 as unique source of information on the safety and effectiveness of authorised medicines. This platform is openly and accessible which includes information on observational post-authorisation research in medicines already marketed in EuropePSNResearch

and some infor that includes is:

  • Study protocols
  • Study results
  • Related publications
Data from 31st f July 2017 – EU PAS Register Platform

All the information at the EU PAS Register helps to reduce publication bias through increased transparency of medicines research, improves the quality of post-authorisation studies by facilitating peer-review of protocols and results, promotes collaboration among stakeholders, and ensures compliance with EU pharmacovigilance legislation requirements.

 The platform is recommended in the following cases: scientific publications, guidelines and textbooks. Although initially the main aim of The EU PAS Register was to collect studies conducted in the European Union, researchers from outside the EU are also registering studies to increase transparency of their research.

The EU PAS Register was developed through the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), which is coordinated by EMA to support research in pharmacoepidemiology and pharmacovigilance.

If you want to consult more info abour EU PAS Register Platform, please click on the link below:

EU PAS Register


The EMA Agreed on principles for involving young people under 18 in their activities

New principles give a voice to patients, consumers and carers under age 18 can make an important contribution to EMA’s committee discussions on medicines by sharing their experience and perspectives of living with a disease or condition.

These principles set out best practice for the interaction between parties on:

  • Discussion in small groups
  • Provision of specific support
  • Use of appropriate language
  • Obtaining parental consent
  • Protection of personal data
  • The privacy of the young patients.

 

The key forum in which young people could participate in the Agency’s activities would be its Paediatric Committee (PDCO), but experience has demonstrated that the Committee for Medicinal Products for Human Use (CHMP), the Pharmacovigilance Risk Assessment Committee (PRAC) and the Scientific Advice Working Party (SAWP) can also benefit from this input when these groups review medicines for children.

For more information about this notice, please check the links below:

Involving young people in EMA activities

THE EMA HOME

PRINCIPLES OF INVOLVING YOUNG PEOPLE ON THE EMA´s ACTIVITIES


FDA Panel Recommends Approval for the First Gene Therapy in Leukemia Treatment

A FDA panel opened a new era in medicine unanimously recommending that the agency approve the first-ever treatment that genetically alters a patient’s own cells to fight cancer, transforming them into what scientists call “a living drug” that powerfully bolsters the immune system to shut down the disease.

The treatment will be The First Gene Therapy ever to reach the market throw FDA approval. 

A single dose of the resulting product has brought long remissions, and possibly cures, to scores of patients in studies who were facing death because every other treatment had failed. The panel recommended approving the treatment for B-cell acute lymphoblastic leukemia that has resisted treatment, or relapsed, in children and young adults aged 3 to 25.

In 2012, as a 6-year-old patient was treated in a study at the Children’s Hospital of Philadelphia. Severe side effects — raging fever, crashing blood pressure, lung congestion — nearly killed her. But she emerged cancer free, and has remained so. 

Her father said to FDA comitte“I hope that someday all of you on the advisory committee can tell your families for generations that you were part of the process that ended the use of toxic treatments like chemotherapy and radiation as standard treatment, and turned blood cancers into a treatable disease that even after relapse most people survive.”

The main evidence  presented by the sponsor to the FDA came from a study of 63 patients who received the treatment from April 2015 to August 2016:

  • 52 of them, (82.5%) went into remission — a high rate for such a severe disease.
  • 11 of them died

As NY times sahred on their interview: “It’s a new world, an exciting therapy,” said Dr. Gwen Nichols, the chief medical officer of the Leukemia and Lymphoma Society, which paid for some of the research that led to the treatment. The next step,  will be to determine “what we can combine it with and is there a way to use it in the future to treat patients with less disease, so that the immune system is in better shape and really able to fight. This is the beginning of something big.”


FDA takes steps in Drug Competition to Improve Patient Access

The U.S. Food and Drug Administration (FDA), is taking two new important steps to increase competition in the market for prescription drugs, and facilitate entry of lower-cost alternatives.

The agency published a list of off-patent, off-exclusivity branded drugs without approved generics, and also implemented, for the first time, a new policy to expedite the review of generic drug applications where competition is limited.

To encourage generic drug development, the FDA posted a list of branded drugs that have no listed patents or exclusivities and for which the agency has yet to approve a generic drug application (known as an Abbreviated New Drug Application or ANDA). The agency also intends to expedite the review of any generic drug application for a product on this list to ensure that they come to market as expeditiously as possible.

The FDA is also announcing a change to its policy on how the agency prioritizes its review of generic drug applications. The FDA will expedite the review of generic drug applications until there are three approved generics for a given drug product. The agency is revising the policy based on data that indicate that consumers see significant price reductions when there are multiple FDA-approved generics available.

These actions follow closely the FDA’s announcement of a public meeting to be held on July 18, 2017, to solicit input on places where the FDA’s rules – including the standards and procedures related to generic drug approvals – are being used in ways that may create obstacles to generic access, instead of ensuring the vigorous competition Congress intended.

These are the first of a series of steps the agency intends to take to help tackle this important issue. The agency will unveil additional aspects of this plan in the near future and will continue to communicate with the public as additional elements of this plan are implemented. These actions reflect the administration’s broader work to improve access to prescription drugs.

 


New Platform for parallel consultation will provide advice to medicine developers and facilitate access to medicines for patients

 

The European Medicines Agency (EMA) and the European Network for Health Technology Assessment (EUnetHTA) are stepping up their efforts to provide developers of medicines with simultaneous, coordinated advice on their development plans and facilitate alignment of data requirements.

This new initiative replaces the existing tool for parallel scientific advice by EMA and HTA bodies which required medicine developers to contact Member States’ HTA bodies individually. It also builds on previous initiatives and pilots on HTA-regulatory collaboration led by EMA, EUnetHTA and the European CommissionExternal link icon (see notes).

Medicines developers will need to notify simultaneously EMA and EUnetHTA of their intention to request parallel advice. EUnetHTA’s Early Dialogue Secretariat, recently created to facilitate such consultations, will then coordinate the involvement of the HTA bodies that will take part in the parallel advice, taking into account the preferences of the requester.

EUnetHTA created the Early Dialogues Working Party (EDWP), composed of HTA bodies with demonstrated experience in early dialogues/scientific advice, to ensure high-quality advice and consistency over time.

The main benefits of this new platform will be:

  • increased mutual understanding and problem solving ability through a more structured interaction between EMA and HTA bodies;
  • improved coordination with, and greater participation of HTA bodies, as a result of the creation of an Early Dialogue Working Party and an Early Dialogue Secretariat at EUnetHTA;
  • streamlined logistics for the requesters.

These advantages are expected to lead to more robust outcomes resulting from the parallel consultation on evidence-generation plans for pharmaceuticals.

 

For more information, just click at the following link:
EMA – interaction to align data requirements

 


PSN Research attended the 18th EULAR Congress of Reumathology celebrated in Madrid last 14th to17th of June

 

 

 

Rafael Zurita (Genaral Director) and Alain Baleydier (France office Director) from PSN Research, attended the 18th EULAR Congress 2017 14-17 of June  in Madrid. 

This is one of the most relevant event during the year for PSN Research as Reumathology is one of the most important Areas of Expertise for PSN RESEARCH 

The Congress, offered a wide range of topics including:

  • Clinical Innovations

  • Clinical Translational Research

  • Basic Science

 

In addition, PSN Research attended at EULAR 2017 meetings organised by People with Arthritis and Rheumatism in Europe (PARE), by Health Professionals in Rheumatology (HPR), and by the Healthcare Industry. 

 

EULAR congress have been received tremendous interest

in terms of participation and quality of contributions

 

 

 

 

It received more than 4.850 abstract submissions, which is by far the highest ever at a EULAR congress. A total of 347 were accepted as oral presentations this year, and the congress features 180 sessions and poster tours with 355 speakers. Out of the 2,336 poster displays spread over 3 days, 461 posters will be explained in 45 themed poster tours.

These numbers reflect the availability of increased information on the impact, burden, and cost of these diseases for society and a significantly improved ability to diagnose and treat them.

For more information about the EULAR Congress please click the links below:

EULAR CONGRESS 2017 -Madrid
EULAR PROGRAM -2017
EULAR HOME 

 


Pulmonary Arterial Hypertension (PAH): Workshop on 12th June co-organised by The EMA for Children with PAH

Pulmonary Arterial Hypertension is a disorder of the blood vessels leading to the lungs, in which the blood pressure in the pulmonary artery becomes high. PAH is a serious, debilitating disease that affects both children and adults but the condition is rare in children and the signs and symptoms often differ from those seen in adults.

The European Medicines Agency (EMA), the United States Food and Drug Administration (FDA) and Health Canada are co-organising a workshop to discuss the requirements for the development of medicines for pulmonary arterial hypertension (PAH) that address the high unmet medical needs of children.

The workshop will bring together leading experts and stakeholders in PAH across the globe:

  • REGULATORS
  • RESEARCHERS
  • CLINICIANS
  • HEALTHCARE PROFESSIONALS
  • PATIENTS
  • PHARMACEUTICAL INDUSTRY REPRESENTATIVES

The objectives of the event are to:

  1. Analyse the problems related to the conduct of clinical trials in children with PAH,
  2. Refine endpoints and study design to address the challenges identified,
  3. Set priorities for future research in specific medicine development aspects,
  4. Provide medicine developers with more guidance specific to global product development, taking into account current limitations 

For further information about this Workshop. please click at the links below:

EMA/FDA/Health Canada WORKSHOP INFO
WORKSHOP PROGRAMME

 

 


The EMA publish a New Action Plan to support SMEs in pharmaceutical innovation

16 ACTIONS IDENTIFIED FOR IMPLEMENTATION IN 2017-2020

 

The European Medicines Agency (EMA) has published today an action plan for small and medium-sized enterprises (SMEs), which aims to foster innovation and support SMEs in the development of novel human and veterinary medicines.

SMEs are the backbone of Europe’s economy, representing:

  • The 99% of all businesses in the European Union (EU) 
  • SMEs are providing 2/3 of total private sector employment
  • SMEs are a motor of innovation and play a major role in the development of new medicines.

To support SMEs throughout all stages of medicine development, EMA’s SME Office provides active regulatory, financial and administrative support to registered SMEs. More than 1,700 companies are currently registered with the Agency operating in the human and veterinary fields.

 

The plan covers four key areas and lists a series of new and enhanced actions:

1. Awareness of EMA’s SME initiative

2. Training and education

3. Support the development of innovative medicines

4. Engagement with SMEs, EU partners and stakeholders

EMA has also published today its SME office 2016 annual report providing an overview of SME-related activities in 2016 and highlights incentives and platforms that SMEs can leverage to advance innovative developments and regulatory strategies.

Please if you want to consult the original documents just click on the links below:

Framework for collaboration with academia

Europe’s next leaders: the Start-up and Scale-up Initiative

SME office 2016 annual report

10th Anniversary of the SME initiative


Approval for New EudraVigilance system for collection and monitoring of suspected Adverse Reactions

The European Medicines Agency (EMA) will launch a new and improved version of EudraVigilance, the European information system of suspected adverse reactions to medicines that are authorised or being studied in clinical trials in the European Economic Area (EEA). The new version of EudraVigilance will go live on 22 November 2017 (announcement of the EMA Management Board) with enhanced functionalities for reporting and analysing suspected adverse reactions.

The enhancements for reporting and analysing suspected adverse reactions of the new EudraVigilance system will support better safety monitoring of medicines and a more efficient reporting process for stakeholders.

Expected benefits include:

  1. Simplified reporting of individual case safety reports (ICSRs) and the re-routing of ICSRs to Member States as marketing authorisation holders will no longer have to provide these reports to national competent authorities, but directly to EudraVigilance, which will ultimately reduce duplication of efforts. An ICSR provides information on an individual case of a suspected adverse reaction to a medicine;
  2. Better detection of new or changing safety issues, enabling rapid action to protect public health;
  3. Increased transparency based on broader access to reports of suspected adverse reactions by healthcare professionals and general public via the adrreports.eu portal, the public interface of the EudraVigilance database;
  4. Enhanced search and more efficient data analysis capabilities;
  5. Increased system capacity and performance to support large volumes of users and reports (including non-serious adverse reactions originating from the EEA);
  6. More efficient collaboration with the World Health Organization (WHO) as EMA will make the reports of individual cases of suspected adverse reactions within the EEA available to the WHO Uppsala Monitoring Centre (UMC) directly from EudraVigilance; Member States will no longer need to carry out this task.

 

The Agency will support national competent authorities, marketing authorisation holders and sponsors of clinical trials in the EEA through targeted e-learning and face-to-face trainings, webinars and information days. Users can trial the new functions of the EudraVigilance system and the internationally agreed format for ICSRs in a test environment as of 26 June 2017. Further information is available on the EudraVigilance training and support webpage.

If you want more info, just click on the links below:

EudraVigilance

EudraVigilance training and support webpage

Clinical Trial Regulation

Announcement of the EMA Management Board


The European Medicines Agency (EMA) has published its 2016 Annual Report

The European Medicines Agency (EMA) has published its 2016 Annual Report. The report focuses on the Agency’s key achievements in the areas of medicine evaluation, support to research and development of new and innovative treatments and the safety monitoring of medicines in real life.

In 2016, the Agency recommended a marketing authorisation for:

  • 81 medicines for human use, including 27 new active substances
  • 11 medicines from the veterinary side were recommended for approval, including six new active substances

As a result of the safety monitoring of all medicines marketed in the European Union (EU), the product information for over 300 medicines for human use was updated on the basis of new safety data.

This document also contains three interviews with stakeholders and EMA representatives on topics of major interest :

Vaccine hesitancy – a threat to public health;

Creating an agile organisation for the 21st century;

How to reinforce surveillance of antimicrobial consumption.

The last part of the report provides a large amount of data and figures that illustrate the work of EMA and its impact.

Please click on the following links for more info:

2016 ANNUAL REPORT
EMA´s ANNUAL REPORTS AND WORK PROGRAMMS

The EMA and the European Commission have published a New Guide on Biosimilar medicines

The guide was launched last  5th  of May of 2017 at the European Commission’s third stakeholder event on biosimilar medicines, a discussion forum that provides a platform for stakeholders interested in biosimilars, including healthcare professionals, patients, payers, regulators and industry. The EU has pioneered the regulation of biosimilar medicines by establishing a solid framework for their approval and by shaping biosimilar development globally.

The main objective of this document is to increase, even more, the understanding of Biosimilar medicines by Healthcare proffesionals and also by all the stake holders involve as it was previously requested by Organisations from across the EU representing: doctors, nurses, pharmacists and patients have also shared useful views, to ensure that the guide adequately addresses questions relevant to healthcare professionals.

Dr Juan Garcia Burgos, Head of EMA’s Public Engagement Department, was in charge of the public presentation of the guide at launch, referring to the guide as: “this comprehensive reference material is a joint effort to support information and continuous education of healthcare professionals in the EU, and facilitate dialogue with patients.”

 

If you are interesting to check more information or download the Guide, please click on the links below:

NEW GUIDE IN BIOSIMILAR MEDICINES
EMA – PRESS RELEASE

 

 

 

 

 


Next 15th and 16th of May 2017, The 6th Orphan Drugs and Rare Diseases Europe 2017-Congress will be celebrated in Berlin

 

Rare diseases have long been under-researched, with many unaware that such conditions even existed. The global orphan drug market generated nearly $123 billion in 2014 and will continue to grow to reach nearly $191 billion by 2019.

With such growth and innovation, now is the best time to discuss the best strategist to follow. Bearing in mind, Germany is Europe’s largest pharma market and also recognised as having one of the toughest pricing policies in Europe, The  6th annual Orphan Drugs will discuss the controversial German pricing mechanism as well as bring together leading industry professionals to share the different opinions of the latest regulatory developments, exploring how to reduce costs and learn from the latest innovations in the orphan drug landscape.

Some of the speakers during both days 15th and 16th of May 2017 will be from companies as: Aegerion Pharmaceuticals, Institute of Pharmaceutical Research & Technology, Therachon AG, NovoNordisk, Orphan Europe, SYMPTOMA, Alexion Pharma GmbH, ATAXIA UK, etc.

For more information and to register online, please visit: www.orphandrugs-event.com or click on the links below:

ORPHAN DRUG´S HOME
PROGRAMME
VENUE

 


The Global Orphan Drug Conference and Expo has been celebrated in USA from19th to 21th of April 2017

 The World Orphan Drug Congress USA in April 2017,  brings more than 150 elite speakers to educate and inspire 1,000 attendees from big pharma, biotech, payers, patient groups, academics and government bodies. In 2017, World Orphan Drug Congress USA is bringing together the worlds of Scientific Innovation and Commercialization, with 2 tracks in the main conference. By exploring trends in Digital Health, Biosimilars, Gene Therapy, and more, we will uncover the next scientific breakthrough. Examinations of Mergers, Commercialization, Marketing and the Regional Markets will provide insight into this billion-dollar business.

Rare Disease Advocacy World focus on the growing trend of advocacy groups influencing regulation, is having a fantastic sessions

INFLUENCING DRUG DEVELOPMENT –The role of the patient is changing once more. Rare Disease Advocacy World will kick off with industry-led investigation into the impact of patient-industry collaboration.

ADVOCACY IN ACTION- Parent Project Muscular Dystrophy (PPMS), PTC Therapeutics and EveryLife Foundation for Rare Diseases will provide practical insight into how patient groups can impact policymaking and orphan drug development, through realworld examples.  

ACCESS-‘Right to Try’ : Rare Disease Advocacy World is facilitating a multi-stakeholder examination of the latest access strategies, and how they will impact the review of new therapies for rare diseases.

NATIONAL PATIENT ORGANIZATIONS- US, South Africa, Australia, Colombia, New Zealand, Japan, India and Europe will also be discussing the opportunities for rare disease research and development in their respective regions.

During this three days, you could enjoy discussions on topics like: 

  • FUTURE OF ORPHAN DRUGS
  • PRICING & REIMBURSEMENT
  • APPROVAL & ACCESS
  • M&A AND COMMERCIALIZATION
  • PATIENT-CENTRIC RESEARCH
  • REAL-WORLD EVIDENCE
  • MARKETING & COMPETITIVENESS
  • GENE THERAPY
  • SCIENTIFIC INNOVATION
  • REGIONAL MARKET ANALYSIS
  • BIOSIMILARS
  • ROUNDTABLES

For more information about thi event, please click the followin links:

EVENT HOME

AGENDA

 


EUREC-ANCEI 2017 EUROPEAN CONGRESS OF RESEARCH ETHICS COMMITTEES

The Conference will take place next 17 th to 19 th of May 2017 in the auditorium of SJD Barcelona Children’s Hospital, and the Borja Institute of Bioethics of the Ramon Llull University will also collaborate in the organisation of the event.
EUREC‐ANCEI (European Network of Research Ethics Committees–Asociación Nacional de Comités de Ética de la Investigación) Conference, has been organised with lectures, round tables and presentations.They will tackle the following topics:
1. The proposal of a new joint platform for research ethics evaluation, either biomedical or not, by means of European projects.
2. The “Recommendation CM/Rec (2016) of the Committee of Ministers to member States on research on biological materials of human origin”
    and the personal data handling in this context   and Biobanks.
3. The features of generational relationships by means of European Projects which treat the psychological stress on adolescents.
4. The meaningfulness and implications of the Research Ethics Committees’ independence.
5. The impact of the new EU Regulation 536/2014 on the Research Ethics Committees of different European countriesDescription, pros, cons,
     surfeits and deficits.
6. Ethics of research on sequencing and prediction in patients with high risks of psychiatric disorders including children and adolescents
    (the IMAGEMEND project).
7. The research in vulnerable populations. The participation of children in the Research Ethics Committees. The Kids Barcelona Project.
8. The question of what kind of Research Ethics Committee can fit in Europe. A proxy committee or an administrative regulator one.
9. Medical devices: the new regulatory project. Ethical problems in the clinical trials and use of medical devices. The example of fetal surgery.
10. To get European opinions and feed back about the proposed topics a free communications session on the different topics of the conference have     
     been programmed.
11. The future of Research Ethics Committees, perspectives and hopes.
The languages of the Conference will be English and Spanish. However, the texts of the lectures and communications to be published in the Conference Book, will be in English.
If you want to read more information about this event, just click at the followong links :
◊  PROGRAM
◊  REGISTRATION
◊  EVENT HOME PAGE

Workshop on Measuring the Impact of Pharmacovigilance Activities organized by the EMA last December 2016

 

Last 5th and 6th of December 2016 was celebrated The Workshop on Measuring the Impact of Pharmacovigilance Activities in London, organized by the European Medicine Agency.

In January 2016 PRAC adopted a strategy for measuring the impact of pharmacovigilance activities. This relies on the collaboration between stakeholders to assess whether pharmacovigilance systems are fully achieving their public health objectives, and to identify areas for improvement.

The workshop’s objective was to develop methods in impact research and to identify enablers and barriers to measuring the impact of pharmacovigilance. Particular focus on new methods for measuring the impact of product-specific pharmacovigilance activities on clinical practice and health outcomes, as well as the impact of individual pharmacovigilance processes.

This event was an excellent opportunity to bring together the available expertise from partners and stakeholders, including:

Regulatory Bodies

EU and national regulatory agencies

International regulatory bodies

Public Bodies

National Healthauthorities

The European Commission

The WHO

Academia and learned Societies

Healthcare Professional Organisations

Patient and Consumer Organisations

Pharmaceutical Industry Associations

If you want a complete information about the Workshop, please click on  EVENT PRESENTATIONS

Also if you want to see the video available of the workshop, please click on  WORKSHOP VIDEO

 


SERMES CRO, a PSN Research Company in Spain, was attended The Farmaforum 2017 event celebrated last 1st and 2nd of March 2017 in Madrid

The Farmaforum 2017 Brokerage offers business contacts to industry, science and nanotechnology professionals who are looking for potential partners within the field: Pharma, Biopharma, Cosmetic, Biotech and Lab technology to ensure sustainable business development and growth.

The main objective of the event is to create a meeting forum for companies, research institutes, universities and other organizations that are actively engaged within the field of Pharma, Biopharma, Cosmetic, Biotech and Lab Technology. Participants may provide opportunities for collaboration and business based on technology, through aimed-to-agreement bilateral meetings.

At the event you found information of the following topics:

  • Pharmaceutics
  • Health
  • Cosmetics
  • Bio-industries
  • Biotech in Cosmetic
  • Related sectors: logistic, regulations, quality and production.

 

And focused on the following Target Groups:

  • Pharmaceutical & Cosmetic Companies
  • Biotech, Diagnostic and Clinical Trial Industries
  • Laboratory Suppliers
  • Universities, Institutes
  • Organisations looking for Commercial, Technological or Research partners from Europe and beyond.

 

If you wish to see the complete information, please click on the link below:

https://www.b2match.eu/farmaforum2017


The EMA shares the Public Report about the Workshop: “Identifying opportunities for `Big data´ in medicines development and Regulatory Science”

We are currently living in the generation of vast volumes of data, creating new evidence which has the potential to add significantly to the way the benefit-risk of medicinal products.

The EMA and the European Union Medicines Regulatory Network are sharing this report with information on the latest developments in the field of big data from the perspective of different stakeholders. This will begin to clarify how and when the multitude of data sources may contribute to medicinal product development, authorisation and surveillance.

If you wish to have the complete information about this workshop, you could access to the entire report by clicking in the link below:

http://www.ema.europa.eu/docs/en_GB/document_library/Report/2017/02/WC500221938.pdf


ARG, our PSN Research Company in USA, is growing fast since move to Charlottesville

Paul Bishop and Lyle Camblos (co-founders of Atlantic Research Group-ARG), moved their 30-person medical research company from Staunton to Charlottesville nearly four years ago to be closer to their labour pool and attract new employees.

The group saw nearly 50 percent growth last year, company officials said, and expects about 30 percent in 2017.
On the strength of two recent FDA approvals and two more ARG expects this year; Camblos and Bishop expect to add another 300 to 400 employees over the next five to seven years.

If you wish to see the complete information of this notice, please click the link below:
http://www.cvilletomorrow.org/news/article/26410-medical-research-firm-growing-fast-since-move-to/#.WKkGHXeTy1w.facebook

 


PSNResearch Proud to have Supported MND Association International Symposium

PSNResearch was Silver Sponsor of the 27th International Symposium on ALS/MND being run by the Motor Neurone Disease Association. The Symposium is the world’s largest medical and scientific conference solely about Motor Neurone Disease / ALS and attracts over 800 delegates from the research community worldwide. Delegates come to hear about the latest advances in research and clinical management and share research and clinical information. 

Last year’s symposium, which has being held in Dublin from 7th – 9th December 2016, had parallel sessions split into biomedical and clinical themes running throughout the three days. Last year’s symposium has covered a wide range topics including therapeutic strategies, evolving biomarkers and clinical trials.